Plain-English translation of NCT07514260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety trial of , a new injectable medication being developed for weight management. Researchers are giving healthy adults either the medication or a placebo (inactive injection) over 12 weeks to see how their bodies handle it, whether they experience any side effects, and how the medication moves through their system. This is one of the first steps in testing a new treatment in humans.
Before this medication can be offered to patients who need help with weight management, researchers need to make sure it is safe and that people can tolerate it well. This early trial gathers that essential safety information.
You will receive subcutaneous injections (shots under the skin) of either the new medication or a placebo once a week for 12 weeks. You will not know which group you are in — that is decided randomly. Throughout the study, you will have visits where researchers check how you are feeling, draw blood to monitor your health, and ask about any side effects or discomfort you experience. The study involves two separate parts with similar schedules.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
AbbVie
Enrollment target
~24 participants
Started
March 2026
Primary completion
January 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2026.